Xin Gao, MD
Hematology & Oncology · Boston, MANPI 1851653489
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Eli Lilly at 30.6% of the total. 2025 is the largest year on record at $6,096, 3.2 times the $1,917 reported in 2019.
Across 29 payments — averaging $804.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$7K
- Myovant Sciences Inc.$5K
- ADC Therapeutics America, Inc.$3K
- Bayer$3K
- Dendreon Pharmaceuticals LLC$1K
- Johnson & Johnson$1K
- plus $3K from 5 others
Across 418 payments — averaging $13,681 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2.1M
- Takeda Pharmaceuticals U.S.A., Inc.$1.6M
- Merck$816K
- Regeneron$413K
- Novartis$306K
- Exelixis Inc.$163K
- plus $300K from 5 others
What the payments were for
- Consulting fees$12,93355%
- Speaking & faculty fees$8,92138%
- Travel & lodging$2761%
- Food & beverage$1,1955%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 10 | $7,140 |
| Myovant Sciences Inc. | 1 | $4,650 |
| ADC Therapeutics America, Inc. | 1 | $3,046 |
| Bayer | 3 | $2,789 |
| Dendreon Pharmaceuticals LLC | 2 | $1,400 |
| Johnson & Johnson | 2 | $1,365 |
| Exelixis Inc. | 2 | $1,237 |
| Janssen Scientific Affairs, LLC | 2 | $937 |
| Sanofi | 4 | $403 |
| Genentech USA, Inc. | 1 | $237 |
| Pfizer | 1 | $133 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ORGOVYX$4,650
- Erleada$2,245
- Non-Covered$1,587
- PROVENGE$1,400
- Cabometyx$1,225
- Nubeqa$1,154
- NO PRODUCT DISCUSSED$287
How this compares
$23,337 in reported general payments places this provider in the 75th percentile of 374 hematology & oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 51 | $623,792 |
| CabometyxCabozantinib S-Malate | 17 | $423,589 |
| FotivdaTivozanib Hcl | 13 | $372,720 |
| InlytaAxitinib | 12 | $190,200 |
| Abiraterone Acetate | 48 | $153,568 |
| OrgovyxRelugolix | 11 | $29,126 |
| Dexamethasone | 13 | $373 |
| Duloxetine Hcl | 16 | $288 |
| Bicalutamide | 24 | $277 |
| Prednisone | 27 | $164 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerNubeqa | $2,789 | $623,79251 claims |
| Exelixis Inc.Cabometyx | $1,237 | $423,58917 claims |
| PfizerInlyta | $133 | $190,20012 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $937 | $153,56848 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 374 hematology & oncology providers in Massachusetts.
Other hematology & oncology in Boston
- David ScaddenBoston$2.6M
- Sara TolaneyBoston$799K
- Matthew DavidsBoston$693K
- Julio HajdenbergBoston$583K
- Paul RichardsonBoston$523K
- Seth WanderBoston$464K
- Corey CutlerBoston$454K
- Hanny Al-SamkariBoston$412K
- Rupal BhattBoston$380K
- Matthew Vander HeidenBoston$355K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.